2.75 semaglutide 7.2mg achieved 20.7% weight loss in STEP UP obesity trial Digital pharmacy to offer weight-loss

People prescribed the new generation of weight loss drugs may not receive sufficient nutritional guidance to support safe and sustainable weight loss, leaving them vulnerable to nutritional deficiencies and muscle loss, say experts at UCL and the University of Cambridge.

Whilst all GLP-1RAs use has increased, the largest change was seen in patients using tirzepatide and semaglutide ([figure 1B][1])

Retatrutide UK Empower Your Research, Unlock Weight Loss Innovation

Headaches are a common side effect during semaglutide treatment, affecting up to 20% of users in clinical trials

By inhibiting the latent GDF8, SRK-015 achieves high selectivity with minimal side effects

$150 off your first month